 - Dose escalation cohorts: Patients with histologically or cytologically confirmed diagnosis of malignancy including lymphoma with demonstrated progression of a tumor for whom there is no available therapy likely to convey clinical benefit AND who have not been previously treated with a PD-1PD-L1 inhibitor. These patients do not require measurable disease 